Parkinson's Discovery Suggests We Could Have an FDA-Approved Treatment Already

Parkinson's Discovery Suggests We Could Have an FDA-Approved Treatment Already

Researchers have discovered how a surface protein on brain cells, called Aplp1, can play a role in spreading material responsible for Parkinson's disease from cell to cell in the brain.

Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed in two earlier studies that missed their main goals.

Parkinson’s Discovery Suggests We Could Have an FDA-Approved Treatment Already : ScienceAlert – Monkey Viral

Researchers have discovered how a surface protein on brain cells, called Aplp1, can play a role in spreading material responsible for Parkinson’s disease from cell to cell in the brain. Promisingly, an FDA-approved cancer drug that targets another protein – Lag3 – which interacts with Aplp1 – was found to block this process in mice. […]

Anti-Alpha-Synuclein Antibody Prasinezumab Enters Phase 3 Development

Roche advances prasinezumab into phase 3 trials for Parkinson disease, aiming to explore its potential as a disease-modifying treatment.

Roche moves ahead with Phase 3 Parkinson’s study despite mixed trial results

Roche and Prothena said they're planning to proceed with a Phase 3 study of an experimental Parkinson’s antibody called prasinezumab, even though two previous mid-stage trials failed to meet their primary endpoints.